Nkarta (NKTX) Cash from Financing Activities (2019 - 2026)
Nkarta's quarterly Cash from Financing Activities came in at $6000.0 in Q1 2026, down 90.62% quarter-over-quarter from $64000.0 in Q4 2025.
Nkarta has reported Cash from Financing Activities for 8 years, with the latest figure at $6000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Financing Activities changed N/A year-over-year to $6000.0; the trailing twelve-month figure through Mar 2026 stood at $147000.0 (up 180.77% YoY), and the FY2025 full-year result was $141000.0, down 99.94% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $6000.0, down from $64000.0 in the prior quarter.
- The five-year high for Cash from Financing Activities was $226.3 million in Q1 2024, with the low at -$368000.0 in Q2 2024.
- Average Cash from Financing Activities over 5 years is $31.9 million, with a median of $131500.0 recorded in 2022.
- Peak annual rise in Cash from Financing Activities reached 22626500.0% in 2024, while the deepest fall reached 193.16% in 2024.
- Tracing NKTX's Cash from Financing Activities over 5 years: stood at $424000.0 in 2022, then tumbled by 30.42% to $295000.0 in 2023, then slumped by 37.63% to $184000.0 in 2024, then sank by 65.22% to $64000.0 in 2025, then slumped by 90.62% to $6000.0 in 2026.
- The last three Cash from Financing Activities figures came in at $6000.0 (Q1 2026), $64000.0 (Q4 2025), and $77000.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 7.00 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -600,000.00 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 53,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -538.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -802.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 15.71 Mn |
| 10 | Nkarta | 232.80 Mn | 232.80 Mn | - | 6,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6,000.00 |
| Mar 31, 2026 | 6,000.00 |
| Dec 31, 2025 | 64,000.00 |
| Dec 31, 2025 | 64,000.00 |
| Jun 30, 2025 | 77,000.00 |
| Jun 30, 2025 | 77,000.00 |
| Dec 31, 2024 | 184,000.00 |
| Dec 31, 2024 | 184,000.00 |
| Sep 30, 2024 | 2,000.00 |
| Sep 30, 2024 | 2,000.00 |
| Jun 30, 2024 | -368,000.00 |
| Jun 30, 2024 | -368,000.00 |
| Mar 31, 2024 | 226.27 Mn |
| Mar 31, 2024 | 226.27 Mn |
| Dec 31, 2023 | 295,000.00 |
| Dec 31, 2023 | 295,000.00 |
| Jun 30, 2023 | 395,000.00 |
| Jun 30, 2023 | 395,000.00 |
| Mar 31, 2023 | 1,000.00 |
| Mar 31, 2023 | 1,000.00 |
| Dec 31, 2022 | 424,000.00 |
| Dec 31, 2022 | 424,000.00 |
| Sep 30, 2022 | 2.56 Mn |
| Sep 30, 2022 | 2.56 Mn |
| Jun 30, 2022 | 215.95 Mn |
| Jun 30, 2022 | 215.95 Mn |
| Mar 31, 2022 | 79,000.00 |
| Mar 31, 2022 | 79,000.00 |
| Dec 31, 2021 | 2,000.00 |
| Dec 31, 2021 | 2,000.00 |
| Sep 30, 2021 | 188,000.00 |
| Sep 30, 2021 | 188,000.00 |
| Jun 30, 2021 | 255,000.00 |
| Jun 30, 2021 | 255,000.00 |
| Mar 31, 2021 | 757,000.00 |
| Mar 31, 2021 | 757,000.00 |
| Dec 31, 2020 | -299,000.00 |
| Dec 31, 2020 | -299,000.00 |
| Sep 30, 2020 | 322.01 Mn |
| Sep 30, 2020 | 322.01 Mn |
| Jun 30, 2020 | 8.81 Mn |
| Jun 30, 2020 | 8.81 Mn |
| Mar 31, 2020 | -709,000.00 |
| Mar 31, 2020 | -709,000.00 |
| Dec 31, 2019 | 5.14 Mn |
| Dec 31, 2019 | 5.14 Mn |
| Sep 30, 2019 | 38.43 Mn |
| Sep 30, 2019 | 38.43 Mn |